Dr. Dave Madge
Project Director (Europe) IDSU
Dr Madge received his B.S. in chemistry from Bangor University in 1984 and his Ph.D. in organic chemistry from Imperial College, London, in 1994.
From 1984 to 1987 Dave worked on the synthesis of fluorinated building blocks, moving in 1987 into a role as a medicinal chemist at the Wellcome Foundation and taking time out to complete a Ph.D. working on the synthesis of new ligands for P.E.T. scanning. In 1995 Dave joined a new integrated biomedical research group at University College, London, as co-founder of the medicinal chemistry group. In this role Dave helped establish new drug discovery projects as collaborative and/or commercial ventures with other scientists at UCL. During this period Dave established and coordinated medicinal chemistry for a neuroscience and an anti-infective company, both of which were acquired by pharma. In 2001 Dave and colleagues established a medicinal chemistry services company, NCE Discovery (now Domainex) which Dave joined as chief operating officer. In 2005 Dave joined a new ion channel drug discovery company, Xention, as VP, Chemistry, becoming VP, Research in 2009. During his time at Xention Dave managed discovery and development projects in several therapeutic areas as both internal projects and collaborative ventures with other organisations, ultimately resulting in the partnering of clinical-stage molecules for cardiology and respiratory targets.s.
Dave has produced over 80 articles and patents, and has presented at international conferences on projects directed towards autoimmune, cardiology and CNS targets. He has discovered and advanced molecules to Phase II for CNS, cardiology, and respiratory indications..